Omeros Reports Allowance of Additional Patent for Ophthalmology Product OMS302
SEATTLE, March 29, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today reported the allowance by the US Patent and Trademark Office (USPTO) of an additional patent claiming intraocular surgical methods of using OMS302, the Company's ophthalmological PharmacoSurgery™ product. The issued patent will have a term extending through July 2023. Currently in Phase 3 clinical development, OMS302 is designed to maintain intraoperative mydriasis (pupil dilation) and reduce pain in the early postoperative period in patients undergoing intraocular lens replacement surgery, including cataract surgery and refractive lens exchange.
This patent extends coverage for OMS302 and further expands Omeros' established PharmacoSurgery intellectual property portfolio. The drug product demonstrated statistically significant superiority over placebo in maintenance of intraoperative mydriasis and reduction of pain in Omeros' Phase 2b clinical trial and first Phase 3 clinical trial. These positive data played a role in the USPTO's decision. Omeros plans to begin enrolling patients next month in its second OMS302 Phase 3 clinical trial.
Omeros is building a patent portfolio for OMS302 focused on protecting both the drug product's composition and method of use. Omeros currently is preparing additional patent applications directed to OMS302 that, if allowed, would further extend its patent protection until at least 2033.